tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robert Willoughby, 31 are a BUY (65.96%), 14 are a HOLD (29.79%), 2 are a SELL (4.26%).
Analyst Robert Willoughby, currently employed at CREDIT SUISSE, carries an average stock price target met ratio of 42.86% that have a potential upside of 5.96% achieved within 33 days.
Robert Willoughby’s has documented 86 price targets and ratings displayed on 7 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CVS, CVS Health Corp at 08-Aug-2022.
Analyst best performing recommendations are on ALGN (ALIGN TECHNOLOGY).
The best stock recommendation documented was for ALGN (ALIGN TECHNOLOGY) at 3/8/2017. The price target of $110 was fulfilled within 7 days with a profit of $6.28 (6.05%) receiving and performance score of 8.65.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$250
$78.59 (45.85%)
$555
27 days ago
(25-Mar-2025)
11/12 (91.67%)
$80 (47.06%)
332
Buy
$235
$63.59 (37.10%)
$270
1 months 3 days ago
(18-Mar-2025)
14/36 (38.89%)
$70.47 (42.83%)
93
Buy
$255
$83.59 (48.77%)
$260
2 months 7 days ago
(14-Feb-2025)
9/13 (69.23%)
$50.11 (24.46%)
89
Buy
$260
$88.59 (51.68%)
$250
2 months 15 days ago
(06-Feb-2025)
5/13 (38.46%)
$41.62 (19.06%)
273
Buy
$280
$108.59 (63.35%)
$310
3 months 15 days ago
(06-Jan-2025)
1/2 (50%)
$61.12 (27.92%)
2
What Year was the first public recommendation made by Robert Willoughby?
